Suministro de Ciclosilicato de sodio y Zirconio (DOE)
TED · 359264-2026Award noticeawardedNo deadline given
Buyer
NameOSAKIDETZA - Servicio Vasco de Salud - Organización Central
CountryES
Published2026-05-27
Deadline—
Value
Estimated€313,731 · 313,731.43 EUR
Awarded€216,367 · 216,366.5 EUR
WinnerASTRAZENECA FARMACEUTICA SPAIN, S.A.
Who already wins at this buyer
Firms with recorded awards from OSAKIDETZA - Servicio Vasco de Salud - Organización Central in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| PFIZER, S.L. | 5 | €67,637,810 | 2026-10-09 |
| EDWARDS LIFESCIENCIES, S.L. | ABBOTT MEDICAL ESPAÑA SA | MEDTRONIC IBÉRICA, S.A. | BOSTON SCIENTIFIC IBÉRICA, S.A. | MERCÉ V. ELECTROMEDICINA, S.L. | PALEX MEDICAL | SAGITTAE MEDICAL S.L | SERMEBI 97 SL | 5 | €40,141,054 | 2026-09-18 |
| ASTRAZENECA FARMACEUTICA SPAIN, S.A. | 5 | €14,397,824 | 2026-10-22 |
| TAKEDA FARMACÉUTICA ESPAÑA, S.A. | 5 | €10,796,370 | 2026-10-16 |
| ROCHE FARMA, S.A. UNIPERSONAL | 4 | €130,837,823 | 2026-09-08 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Suministro de Ciclosilicato de sodio y Zirconio (DOE)
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-09-07 | Suministro de Tocilizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-06-04 | Suministro de Risankizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-05-27 | Suministro de Sirolimus (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-09-25 | Suministro de concizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-09-03 | Suministro de Emicizumab (DOE) y Risdiplam (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-10-23 | Suministro de Tildrakizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |